SCHEMBL4713786

SCHEMBL4713786

CCOC(=O)c1cc2[nH]c(=O)ccc2n1Cc1cccc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
ALDH1A1 P00352 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 2/20 0.48
MAPK1 P28482 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
POLB P06746 1/20 0.48
TSHR P16473 1/20 0.48
ATM Q13315 1/20 0.48
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NOD2 Q9HC29 1/20 0.47
NOD1 Q9Y239 1/20 0.47
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
F10 P00742 3/20 0.46
ALOX5 P09917 2/20 0.46
MEN1 O00255 2/20 0.46
LMNA P02545 2/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717121 0.90 MAPT (0.58) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL4715682 0.89 ALDH1A1 (0.51) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL4715652 0.86 MAPT (0.49) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL4716178 0.83 MAPT (0.47) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL6307843 0.79 NOD2 (0.74) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL4712174 0.77 MAPT (0.51) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL1503984 0.77 NOD2 (0.67) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL4653221 0.77 F10 (0.59) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL3201430 0.76 NOD2 (0.63) MAPTALDH1A1TDP1KDM4EMAPK1
SCHEMBL4716291 0.76 NOD2 (0.52) MAPTALDH1A1TDP1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 MAPT 1831/4885ALDH1A1 3407/4885TDP1 983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.